Three RI-MUHC researchers honoured with prestigious Canada Research Chairs
Sylvie Lambert, Marc Martel and Mathieu Roy are emerging leaders in research domains ranging from chronic illnesses...
Triple-negative breast cancer: new hope for an existing drug
RI-MUHC team takes another step toward precision medicine by targeting a biomarker of CDK4/6 inhibitor efficacy in breast cancer, including triple-negative...
Prescribing personalized lifestyle interventions to improve prostate cancer treatments
David Labbé of the RI-MUHC co-leads a new project recently funded by the Marathon of Hope Cancer Centres...
Researchers find a possible therapeutic target in the “genetic landscape” of aggressive and deadly pediatric brain tumours
A new study reveals that PFA ependymoma brain tumours display...
Major funding awards for seven RI-MUHC trainees
A Banting Fellowship and six Vanier Scholarships were awarded in 2024
Increasing clinical trial expertise at the RI-MUHC
The RI-MUHC ACT-CTU reports on the realization of its vision for 2024 to build a clinical trials community and strengthen trial capabilities at the RI-MUHC
RI-MUHC researchers work to accelerate precision medicine for cancer in Canada
Three additional RI-MUHC research projects funded by the Marathon of Hope Cancer Centres Network
Congratulations to our 2024 CLIC winners and finalists
RI-MUHC researchers and trainees collaborate on four winning teams
RI-MUHC study uses AI to understand liver cancer
A new publication describes the use of ALiX, a unique AI model, to analyze data from liquid biopsy
Annual Clinical Research Day event highlights RI-MUHC services and expertise in clinical trials
The Centre for Innovative Medicine and many other clinical research support teams introduced their skills...